CoChat

Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial

Open access
and the Saudi Critical Care Trials group, Arabi, Yaseen M., Asiri, Ayed Y., Assiri, Abdullah M., Aziz Jokhdar, Hani A., Alothman, Adel, Balkhy, Hanan H., AlJohani, Sameera, Al Harbi, Shmeylan, Kojan, Suleiman, Al Jeraisy, Majed, Deeb, Ahmad M., Memish, Ziad A., Ghazal, Sameeh, Al Faraj, Sarah, Al-Hameed, Fahad, AlSaedi, Asim, Mandourah, Yasser, Al Mekhlafi, Ghaleb A., Sherbeeni, Nisreen Murad, Elzein, Fatehi Elnour, Almotairi, Abdullah, Al Bshabshe, Ali, Kharaba, Ayman, Jose, Jesna, Al Harthy, Abdulrahman, Al Sulaiman, Mohammed, Mady, Ahmed, Fowler, Robert A., Hayden, Frederick G., Al-Dawood, Abdulaziz, Abdelzaher, Mohamed, Bajhmom, Wail, Hussein, Mohamed A. · 2020 · Trials
Cited by 128

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

The MIRACLE trial (MERS-CoV Infection tReated with A Combination of Lopinavir/ritonavir and intErferon-β1b) investigates the efficacy of a combination therapy of lopinavir/ritonavir and recombinant interferon-β1b provided with standard supportive care, compared to placebo provided with standard supportive care, in hospitalized patients with laboratory-confirmed MERS. The MIRACLE trial is designed as a recursive, two-stage, group sequential, multicenter, placebo-controlled, double-blind randomized controlled trial. The aim of this article is to describe the statistical analysis plan for the MIRACLE trial. The primary outcome is 90-day mortality. The primary analysis will follow the intention-to-treat principle. The MIRACLE trial is the first randomized controlled trial for MERS treatment. Trial registration: ClinicalTrials.gov,NCT02845843. Registered on 27 July 2016.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13063-019-3846-x

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 128

Metadata

Authors
and the Saudi Critical Care Trials group, Arabi, Y. M., Asiri, A. Y., Assiri, A. M., Aziz Jokhdar, H. A., Alothman, A., Balkhy, H. H., AlJohani, S., Al Harbi, S., Kojan, S., Al Jeraisy, M., Deeb, A. M., Memish, Z. A., Ghazal, S., Al Faraj, S., Al-Hameed, F., AlSaedi, A., Mandourah, Y., Al Mekhlafi, G. A., Sherbeeni, N. M., Elzein, F. E., Almotairi, A., Al Bshabshe, A., Kharaba, A., Jose, J., Al Harthy, A., Al Sulaiman, M., Mady, A., Fowler, R. A., Hayden, F. G., Al-Dawood, A., Abdelzaher, M., Bajhmom, W., & Hussein, M. A.
Venue
Trials
Published
2020-01-03
Volume
21
Issue
1
Pages
8-8
ISSN
1745-6215 (ISSN-L)
OpenAlex
W3004164092
Cited by
128
References
5
FWCI
3.74
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. https://app.cochat.ai/papers/10.1186/s13063-019-3846-x
The paper
and the Saudi Critical Care Trials group, Arabi, Y. M., Asiri, A. Y., Assiri, A. M., Aziz Jokhdar, H. A., Alothman, A., Balkhy, H. H., AlJohani, S., Al Harbi, S., Kojan, S., Al Jeraisy, M., Deeb, A. M., Memish, Z. A., Ghazal, S., Al Faraj, S., Al-Hameed, F., AlSaedi, A., Mandourah, Y., Al Mekhlafi, G. A., . . . Hussein, M. A. (2020). Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials. https://doi.org/10.1186/s13063-019-3846-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.